Literature DB >> 2116774

Selective polyclonal increase of immunoglobulin G1 subclass: a link with Sjögren's syndrome.

E M Hay1, A J Freemont, R A Kay, R M Bernstein, P J Holt, R S Pumphrey.   

Abstract

A selective polyclonal increase in IgG1 has been described previously in a group of patients with connective tissue disease; nine of the 16 patients had a prior diagnosis of systemic lupus erythematosus (SLE). A detailed clinical and serological study of 32 patients with this immunoglobulin abnormality has now been made. Most cases showed a characteristic autoantibody profile of antinuclear antibody, rheumatoid factor, and antibodies to Ro and La. Sjögren's syndrome was diagnosed as 'definite' in 16 cases and 'possible' in seven cases by Fox's criteria. The remainder had unclassified connective tissue disease (three), rheumatoid arthritis with dry eyes (two), SLE (one), scleroderma (two), and Raynaud's disease (one). Extraglandular features were invariably present in patients with primary Sjögren's syndrome. The highest concentrations of IgG1 were found in patients with the shortest disease duration. Selective polyclonal increase of IgG1 should alert the doctor to the development of Sjögren's syndrome, usually with extraglandular disease and antibodies to Ro and La.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116774      PMCID: PMC1004103          DOI: 10.1136/ard.49.6.373

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Anticardiolipin antibodies in systemic lupus erythematous.

Authors:  N Snowden; P Wilson; R Pumphrey
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

2.  Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy.

Authors:  G L Schall; L G Anderson; R O Wolf; J R Herdt; T M Tarpley; N A Cummings; L S Zeiger; N Talal
Journal:  JAMA       Date:  1971-06-28       Impact factor: 56.272

3.  Investigation of IgG4 levels in atopic patients using a competitive inhibition assay employing biotinylated IgG4 myeloma and avidin peroxidase.

Authors:  P B Wilson; K J Wood; P Doré; J A Swainson; P E Brenchley; R S Pumphrey
Journal:  J Immunol Methods       Date:  1986-02-27       Impact factor: 2.303

4.  Autoantibodies in lupus and its variants: experience in 1000 patients.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-11

5.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.

Authors:  R M Bernstein; J C Steigerwald; E M Tan
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

6.  Identification of antibodies to acidic antigens by counterimmunoelectrophoresis.

Authors:  R M Bernstein; C C Bunn; G R Hughes
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

7.  Automated filing and reporting in a regional immunology service laboratory using a PET computer.

Authors:  R S Pumphrey
Journal:  Med Inform (Lond)       Date:  1981 Oct-Dec

8.  An enzyme-linked immunosorbent assay for antibodies to native and denatured DNA.

Authors:  J L Klotz; R M Minami; R L Teplitz
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

9.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

10.  Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone.

Authors:  R A Hazelton; A B McCruden; R D Sturrock; W H Stimson
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

View more
  2 in total

Review 1.  Hypergammaglobulinaemia and autoimmune rheumatic diseases.

Authors:  M R Ehrenstein; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

2.  An abnormal T cell repertoire in hypergammaglobulinaemic primary Sjögren's syndrome.

Authors:  R A Kay; E M Hay; P A Dyer; C Dennett; L M Green; R M Bernstein; P J Holt; R S Pumphrey; A W Boylston; W E Ollier
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.